Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trialAlexander E. Perl,Giovanni Martinelli,Jorge E. Cortes,Andreas Neubauer,Ellin Berman,Stefania Paolini,Pau Montesinos,Maria R. Baer,Richard A. Larson,Celalettin Ustun,Francesco Fabbiano,Antonio Di Stasi,Robert Stuart,Rebecca Olin,Margaret Kasner,Fabio Ciceri,Wen-Chien Chou,Nikolai Podoltsev,Christian Recher,Hisayuki Yokoyama,Naoko Hosono,Sung-Soo Yoon,Je-Hwan Lee,Timothy Pardee,Amir T. Fathi,Chaofeng Liu,Xuan Liu,Erkut Bahceci,Mark J. LevisCANCER RESEARCH(2019)引用 31|浏览35暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要